[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fetal-growth-restriction-fgr\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fetal-growth-restriction-fgr":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,91,114,137,167,201],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100643973","advancing-stillbirth-prevention-through-innovative-risk-evaluation-aspire-clinical-study-100643973",false,"NCT07669935","Advancing Stillbirth Prevention Through Innovative Risk Evaluation (ASPIRE) Clinical Study","A Multi-Site, Prospective, Two-Part Longitudinal, Observational Cohort Study Of Pregnant Women To Evaluate Biomarkers For Prediction Of Pregnancy Complications","ASPIRE","Inclusion Criteria:\n\n* Age ≥18 years\n* Nulliparous (no previous births ≥20wk GA)\n* Single viable fetus at the dating ultrasound scan with an ultrasound estimated gestational age of 10 0\u002F7-17 6\u002F7 weeks of gestation\n* Ability to consent and comply with study procedures and follow-up\n\nExclusion Criteria:\n\n* Multiple gestation\n* Inability to provide blood\n* Known fetal chromosomal abnormalities or structural Anomaly (a structural or functional defect with the following three characteristics: 1) of prenatal origin; 2) present at the time of live birth or fetal demise, or in utero; 3) affecting (or has the propensity to affect) the health, survival, or physical or cognitive functioning of the individual\n* Known or anticipated inability to complete study follow-up through delivery at the study site (e.g., planned relocation, transfer of obstetric care to a non-participating institution, or other circumstances making delivery outcome data unavailable)\n* Current or recent (within two months) participation in an interventional clinical study.",true,"FEMALE","18 Years","99 Years",{"count":22,"type":23},5500,"ESTIMATED","OBSERVATIONAL","ASPIRE will be a multi-site, prospective, two-part longitudinal, noninterventional observational cohort study of nulliparous singleton pregnant women to evaluate biomarkers from blood and ocular imaging for prediction of pregnancy complications \\[i.e., preeclampsia (PE), fetal growth restriction (FGR), and gestational diabetes (GDM)\\] and risk of adverse outcomes.",[27,28,29,30,31],"GDM","Preterm Preeclampsia","Preeclampsia","Fetal Growth Restriction (FGR)","Pregnancy Complications","NOT_YET_RECRUITING","2026-06-25",{"date":35,"type":36},"2026-06-29","ACTUAL",{"date":38,"type":23},"2026-07-30",{"date":40,"type":23},"2028-12-01",{"name":42,"class":43},"Medicines360","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":64,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},"100582284","placental-imaging-techniques-100582284","NCT06861309","Placental Imaging Techniques","Evaluation of Innovative Placental Imaging Techniques in Fetal Growth Restriction","Inclusion Criteria:\n\n* Normal-Fetal-Weight Pregnancies Arm: Patient at least 18 to 45 years of age at screening\n* Normal-Fetal-Weight Pregnancies Arm: Non-anomalous, singleton gestation without suspected genetic disorders or growth abnormalities\n* Normal-Fetal-Weight Pregnancies Arm: Low-risk aneuploidy screening, if performed\n* Normal-Fetal-Weight Pregnancies Arm: Intention to deliver at Carilion Roanoke Memorial Hospital (CRMH) or Carilion New River Valley Medical Center (CNRVMC)\n* Normal-Fetal-Weight Pregnancies Arm: Anatomical survey has been performed\n* Normal-Fetal-Weight Pregnancies Arm: Pregnancy without current fetal growth restriction (FGR) diagnosis\n* Normal-Fetal-Weight Pregnancies Arm: Subject willing and able to provide informed consent Note: Verify that the most recent version of the ICF was used to consent the subject\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Patient at least 18 to 45 years of age at screening\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Non-anomalous, singleton gestation without suspected genetic disorders\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Low-risk aneuploidy screening, if performed\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Intention to deliver at Carilion Roanoke Memorial Hospital (CRMH) or Carilion New River Valley Medical Center (CNRVMC)\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Anatomical survey has been performed\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Pregnancy diagnosed with fetal growth restriction (FGR) by estimated fetal weight \\\u003C10th centile or abdominal circumference measurements \\\u003C10th centile\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Subject willing and able to provide informed consent Note: Verify that the most recent version of the ICF was used to consent the subject\n\nExclusion Criteria:\n\n* Normal-Fetal-Weight Pregnancies Arm: Multiple gestations\n* Normal-Fetal-Weight Pregnancies Arm: Known fetal anomaly affecting biometric measurements\n* Normal-Fetal-Weight Pregnancies Arm: Suspected fetal genetic disorder(s)\n* Normal-Fetal-Weight Pregnancies Arm: Suspected fetal infection(s)\n* Normal-Fetal-Weight Pregnancies Arm: Non-English or Spanish-speaking\n* Normal-Fetal-Weight Pregnancies Arm: Unstable housing or transportation\n* Normal-Fetal-Weight Pregnancies Arm: Any other criterion which, in the clinical judgement of the investigator, would make the subject unsuitable for study enrollment.\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Multiple gestations\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Known fetal anomaly affecting biometric measurements\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Suspected fetal genetic disorder(s)\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Suspected fetal infection(s)\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Non-English or Spanish-speaking\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Unstable housing or transportation\n* Fetal-Growth-Restricted (FGR) Pregnancies Arm: Any other criterion which, in the clinical judgement of the investigator, would make the subject unsuitable for study enrollment.","45 Years",{"count":53,"type":23},60,"INTERVENTIONAL",[56],"NA","The goal of this proof-of-concept, case-control, clinical trial is to evaluate the efficacy of using two newer ultrasound technologies, quantitative ultrasound (QUS) and ultrafast power Doppler imaging (uPDI), to evaluate the health of the placenta, visualize blood flow through the placental vasculature by color Doppler imaging in singleton pregnancies with and without fetal growth restriction (FGR).\n\n* Our primary objective is to investigate the ability of using these ultrasound technologies to distinguish healthy pregnancies from those affected by FGR, a condition characterized by a fetal weight below the 10th percentile for the gestational age or abdominal circumference of the pregnancy.\n* Secondary aims include longitudinal evaluation of differences in QUS and uPDI imaging over gestation and changes in these measures with evolution of utero-placental insufficiency including with the development of abnormal umbilical-artery Doppler testing, diagnosis of severe FGR, identification of stillbirth, and detection of preeclampsia or preterm birth.\n\nInvestigators will compare QUS\u002FuPDI imaging and values in pregnancies determined to be healthy by approved, standard-of-care growth ultrasounds to those diagnosed with FGR.\n\nParticipants will receive research ultrasounds with the experimental Verasonics Vantage 256 system (Verasonics, Inc, Kirkland, WA) utilizing uPDI\u002FQUS every three weeks following their routine growth ultrasound evaluation until delivery. Demographic, obstetric, and delivery-related information, as well as portions of subjects' past medical history will be utilized by researchers to further contextualize imaging and variables gathered during the research ultrasounds.",[30,59,29,60,61,31,62,63],"Placental Insufficiency","Still Births","Pregnancy","Pregnancy Outcomes","Ultrasound",[65,66,67,68,69,63,61,31,70,71,72,73,74,75,76,29,77,78,79,80],"Fetal Growth Restriction","FGR","Placental Imaging","Utero-Placental Insufficiency","Growth Restriction","Maternal Fetal Medicine","Ultrafast Power Doppler Imaging","Quantitative Ultrasound","uPDI","QUS","MFM","Stillbirth","Verasonics","Verasonics Vantage 256","Carilion Clinic","Virginia Tech","RECRUITING","2026-05-20",{"date":84,"type":36},"2026-05-22",{"date":86,"type":36},"2025-04-23",{"date":88,"type":23},"2026-11",{"name":79,"class":43},1,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":18,"minAge":98,"maxAge":99,"enrollmentInfo":100,"targetDuration":102,"studyType":24,"phases":4,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":90},"100629366","ai-based-ultrasound-prediction-of-pregnancy-outcomes-in-placental-related-fetal-growth-restriction-mvm-fgr-a-prospective-cohort-study-100629366","NCT07473739","AI-Based Ultrasound Prediction of Pregnancy Outcomes in Placental-Related Fetal Growth Restriction (MVM-FGR): A Prospective Cohort Study","Establishment of a Cohort of Maternal Vascular Malperfusion-Related Fetal Growth Restriction (MVM-FGR) Based on an Etiology-Oriented Diagnostic Pathway: Artificial Intelligence-Assisted Multiparametric Ultrasound Prediction of Pregnancy Outcomes","Inclusion Criteria:\n\n* Singleton pregnancy.\n* Isolated early-onset placental insufficiency-related fetal growth restriction (FGR), with priority given to cases with abnormal umbilical artery Doppler flow.\n* Pregnancies in which expectant management is continued.\n\nExclusion Criteria:\n\n* Multiple pregnancy complicated by selective fetal growth restriction (sFGR).\n* FGR caused by fetal structural anomalies, genetic abnormalities, or intrauterine infection.\n* Twin pregnancy with intrauterine fetal demise (IUFD) of one fetus.","20 Years","43 Years",{"count":101,"type":23},300,"2 Years","The goal of this prospective cohort study is to enroll pregnancies complicated by placental-related fetal growth restriction (FGR) and to develop predictive models for adverse short- and long-term outcomes. This will be achieved by collecting novel intrauterine monitoring indicators along the fetal brain-placenta-heart axis, combined with conventional fetal surveillance parameters, in order to improve risk stratification and guide clinical management, ultimately improving pregnancy outcomes.\n\nThe study will include pregnant women with singleton pregnancies complicated by isolated early-onset placental insufficiency-related FGR, preferably those with abnormal umbilical artery Doppler findings, who elect to continue the pregnancy.\n\nThe main question it aims to answer is:\n\n• Whether a predictive model integrating novel intrauterine monitoring indicators along the fetal brain-placenta-heart axis with conventional monitoring parameters can accurately predict perinatal and neonatal adverse outcomes in pregnancies complicated by placental-related FGR.",[30],"2026-03-11",{"date":107,"type":36},"2026-03-16",{"date":109,"type":36},"2023-01-01",{"date":111,"type":23},"2028-11-30",{"name":113,"class":43},"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":90},"100629105","placental-biology-in-health-and-disease-100629105","NCT07470320","Placental Biology in Health and Disease","Inclusion Criteria:\n\n* Female, aged 18 years or above\n* Willing and able to give informed consent for participation in the study\n* Able to read and understand written and spoken English to comprehend study materials and give informed consent\n* Non-pregnant women in good general health OR pregnant women who fall into one of the following:\n\n  * Healthy pregnancy\n  * Pre-eclampsia (PET) - defined by clinical diagnostic criteria, including hypertension and proteinuria\n  * Gestational diabetes mellitus (GDM) - diagnosed by standard glucose tolerance tests during pregnancy\n  * Fetal growth restriction (FGR) - diagnosed based on fetal weight or Doppler abnormalities\n  * Predisposed to PET - high-risk factors for PET such as maternal type 1 or type 2 diabetes, autoimmune diseases or multiple pregnancies\n\nExclusion Criteria:\n\n* Non-pregnant participants with active health conditions that could confound study outcomes\n* Pregnant participants with conditions unrelated to PET, GDM or FGR that could influence EV profiles e.g. active infections or malignancies",{"count":121,"type":23},360,"Pre-eclampsia (PET) is a condition characterised by high blood pressure and damage to other organs, and is a leading cause of maternal and fetal complications such as fetal growth restriction (FGR). Gestational diabetes mellitus (GDM) involves abnormal blood sugar levels during pregnancy and can have both short and long-term impacts on the health of the mother and child. Both conditions are linked to placental dysfunction but the precise mechanisms behind these links remain unclear.\n\nA major focus of this study is on extracellular vesicles (EVs) which are tiny, bubble-like particles released by the placenta into the mother's and baby's bloodstreams. These EVs act as messengers, carrying proteins, lipids and genetic material that can influence how cells function, even in parts of the body far from the placenta. Notably, the number and content of these EVs change in conditions like PET and GDM, suggesting they may play a role in the development of these complications.\n\nThis single-site, observational, laboratory study aims to investigate how these EVs contribute to maternal health and disease. To enable analysis across different physiological and pathological conditions pregnant participants with healthy pregnancies, pregnancies predisposed to PET and pregnancies complicated by GDM, FGR and PET will be recruited alongside healthy non-pregnant controls. Recruitment will be from the Oxford University Hospitals NHS Foundation Trust and the Nuffield Department of Women's and Reproductive Health, University of Oxford (who fund the research). Demographic and clinical data will be collected as well as blood, urine, breath, placenta, umbilical cord, umbilical cord blood, amniotic fluid and\u002For uterine vein blood samples.\n\nThrough examining EV content and function, it is hoped a better understanding of their role in pregnancy complications will be gained, including their potential as non-invasive biomarkers for early detection and targeted treatments, improving outcomes for mothers and babies worldwide.",[124,125,30,126,127,61],"Pre-eclampsia","Gestational Diabetes Mellitus (GDM)","Pregnancy Induced Hypertension (PIH)","Placenta","2026-03-09",{"date":130,"type":36},"2026-03-13",{"date":132,"type":36},"2025-12-16",{"date":134,"type":23},"2030-05-31",{"name":136,"class":43},"University of Oxford",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":17,"sex":18,"minAge":145,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":166},"100604637","amniotic-fluid--the-preterm-gut-100604637","NCT07152106","Amniotic Fluid & the Preterm Gut","The Impact of Amniotic Fluid on the Development and Microbial Colonization of the Preterm Intestinal Tract: the AMFIBIE Study","AMFIBIE","Inclusion Criteria:\n\n* Maternal age ≥16 years\n* Written informed consent\n* Successful collection of amniotic fluid\n\nExclusion Criteria:\n\n* Pregnancies complicated by fetal congenital and\u002For chromosomal abnormalities.\n* Insufficient proficiency of Dutch or English language","16 Years",{"count":147,"type":23},275,"Background:\n\nNecrotizing enterocolitis (NEC) and sepsis in preterm infants have been linked to intestinal immaturity and preclinical gut microbiota alterations. An important yet understudied contributor in the development of the gastrointestinal tract (GIT) is amniotic fluid (AF). Knowledge is lacking on the critical shifts that may occur in AF in extremely preterm birth. The aim of the current study is to assess the composition of AF using advanced biomedical techniques. Secondary objectives are to assess AF profiles of infants with chorioamnionitis (CAM) and\u002For fetal growth restriction (FGR), assess key metabolites across gestation, correlate AF profiles with neonatal outcomes, and explore associations with early gut microbiota.\n\nMethods:\n\nln this multicenter, prospective, cohort study, AF (\\~5 mL) will be collected from obstetric patients delivering their infants extremely preterm (gestational age (GA) 24+0\u002F7-27+6\u002F7 weeks, n=125), either during vaginal delivery or cesarean section (CS). Additionally, AF samples will be collected from a reference group (n=150), including early midtrimester (GA \\\u003C23+\u002F7 weeks), very early and moderate to late preterm (GA 28+0\u002F6-36+6\u002F7 weeks), and full-term pregnancies (GA 37+0\u002F7-41+6\u002F7 weeks). Thorough characterization of AF will be conducted, including microbial profiling and metabolomics. Microbiota profiling of neonatal fecal samples will be conducted to assess the association between AF and early neonatal gut colonization patterns.\n\nDiscussion and expected results:\n\nAF profiles associated with CAM and\u002For FGR in extremely preterm infants are expected to be identified, as well as relevant associations with neonatal health outcomes (including NEC and sepsis) and early neonatal gut colonization patterns. The current study will not only increase the understanding of the GIT development and the pathogenesis of NEC and sepsis but may also aid in the identification of high-risk infants. In the future, these findings may facilitate early targeted microbiota-based interventions to prevent disease progression and ultimately improve clinical outcomes.",[150,151,152,153,154,30,155,156],"Chorioamnionitis","Chorioamnionitis Affecting Fetus or Newborn","Necrotizing Enterocolitis of Newborn","Neonatal Sepsis, Early-Onset","Neonatal Sepsis, Late-Onset","Preterm Birth Complication","Prematurity Complications","2025-08-28",{"date":159,"type":36},"2025-09-03",{"date":161,"type":36},"2024-10-14",{"date":163,"type":23},"2027-10-14",{"name":165,"class":43},"Maxima Medical Center",2,{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":174,"targetDuration":176,"studyType":24,"phases":4,"briefSummary":177,"conditions":178,"keywords":182,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":200},"100586658","association-of-assisted-reproductive-technologies-parameters-with-the-perinatal-outcome-100586658","NCT06918236","Association of Assisted Reproductive Technologies Parameters With the Perinatal Outcome","Association of Assisted Reproductive Technologies Parameters With the Perinatal Outcome in Singleton and Multiple Pregnancies: A Multicenter Prospective Cohort Study","Inclusion Criteria\n\n* Singleton or multiple pregnancies\n* Live fetus between 11 weeks plus 0 days and 13 weeks plus 6 days of gestation\n\nExclusion Criteria\n\n* Known genetic anomalies diagnosed before or after birth\n* Major fetal defects diagnosed before or after birth, such as acrania, holoprosencephaly, megacystis, exomphalos, congenital heart defects",{"count":175,"type":23},12084,"9 Months","The goal of this prospective cohort study is to examine how different parameters of assisted reproductive technologies (ART) are associated with the perinatal outcome in individuals with singleton or multiple gestations. The main questions it aims to answer are:\n\nAre ART pregnancies associated with a higher risk of:\n\n* Small for gestational age neonates?\n* Fetal growth restriction, either early- or late-onset?\n* Development of preeclampsia?\n* Stillbirth (intrauterine fetal death after 22 weeks not due to known anomalies)?\n* Are certain ART parameters-such as the type of fertilization (e.g., IVF vs. ICSI), embryo stage at transfer, use of fresh vs. frozen embryos, or ovarian stimulation protocols-more strongly associated with adverse outcomes?\n\nAre ART pregnancies associated with placental and umbilical cord abnormalities, including:\n\n* Placenta previa?\n* Vasa previa?\n* Single umbilical artery?\n* Velamentous or marginal cord insertion?\n\nResearchers will compare outcomes between pregnancies conceived through ART and those conceived spontaneously.\n\nParticipants will:\n\n* Be individuals aged 18 or older undergoing routine first-trimester ultrasound between 11 and 14 weeks of gestation\n* Provide detailed medical, obstetric, and ART-related information\n* Undergo routine prenatal assessments, including ultrasound evaluations of fetal growth, Doppler studies, and placental characteristics\n* Have perinatal outcomes such as gestational age at birth, mode of delivery, birthweight, and complications systematically recorded\n\nStatistical models will be used to adjust for confounding factors such as maternal age, BMI, parity, and smoking.\n\nThe aim is to better understand how ART and specific ART parameters may influence maternal and neonatal health and to improve counseling and clinical care for people using fertility treatments.",[30,29,76,179,180,181],"Placenta Previa","Vasa Previa","Small for Gestational Age (SGA)",[183,29,184,185,186,187,188,181,189,190],"fetal growth restriction","stillbirth","placenta previa","vasa previa","Assisted reproductive techniques","ART","IVF","ICSI","2025-04-05",{"date":193,"type":36},"2025-04-09",{"date":195,"type":36},"2024-10-01",{"date":197,"type":23},"2028-12",{"name":199,"class":43},"Aristotle University Of Thessaloniki",6,{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":210,"conditions":211,"keywords":214,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":90},"100584789","cord-blood-s100b-protein-concentration-in-neonates-with-fetal-growth-restriction-100584789","NCT06893926","Cord Blood S100B Protein Concentration in Neonates With Fetal Growth Restriction","Evaluating the Utility of S100B Protein Concentration for Diagnosing Fetal Central Nervous System Hypoxia-Ischemia in Children With Late Fetal Growth Retardation: A Prospective Cohort Study","Study Group - Inclusion Criteria:\n\n1. Women with a full-term pregnancy (≥37 weeks of gestation), singleton.\n2. Pregnancy complicated by FGR.\n\nStudy Group - Exclusion Criteria:\n\n1. Antenatal (at recruitment):\n\n   * Maternal conditions that may affect the blood flow in placental vessels, including smoking, use of illicit stimulant substances, or pregestational diabetes.\n   * Maternal depression requiring pharmacological treatment (e.g., SSRIs).\n2. Intrapartum:\n\n   * Factors indicating a possible intrauterine infection, such as amniotic fluid leakage for more than 15 hours, spontaneous preterm labor, diagnosed intrauterine infection, or symptoms of infection in the mother.\n   * Prolonged labor lasting more than 15 hours.\n\nControl Group - Inclusion Criteria:\n\n1. Women with a full-term pregnancy (≥37 weeks of gestation), singleton.\n2. Pregnancy not complicated by FGR.\n\nControl Group - Exclusion Criteria:\n\n1. Antenatal (at recruitment):\n\n   * Maternal conditions that may affect placental blood flow, such as smoking, use of illicit stimulant substances, pregestational diabetes, or chronic hypertension.\n   * Maternal depression requiring pharmacological treatment (e.g., SSRIs).\n   * Risk factors for intrauterine HI, including abnormal fetal blood flow parameters on ultrasound, abnormal CTG recordings, or the need for intrauterine transfusion.\n2. Intrapartum:\n\n   * Indicators of possible intrauterine infection, such as amniotic fluid leakage for more than 15 hours, spontaneous preterm delivery, diagnosed intrauterine infection, or maternal symptoms of infection.\n   * Risk factors for perinatal HI.\n   * Prolonged labor lasting more than 15 hours (counted from the onset of regular uterine contractions).\n   * Birth weight below the 10th percentile or above the 90th percentile.\n   * Apgar score less than 8 at the 1st, 3rd, 5th, or 10th minute of life.\n   * Abnormal umbilical cord blood gas analysis results, defined as pH \\\u003C 7.15 or BE \\\u003C -9.3 mmol\u002Fl.\n3. Postnatal:\n\n   * Neonatal anemia requiring a top-up transfusion within the first 24 hours of life",{"count":209,"type":23},120,"S100B protein is a biomarker that increases following central nervous system (CNS) damage. Measuring this protein's levels may allow for the early identification of infants at high risk for developmental abnormalities, such as fetal growth restriction (FGR), even on the first day of life, in a non-invasive manner. Early detection could enable timely interventions and rehabilitation, potentially improving the child's prognosis and long-term outcomes. This study investigates two groups of full-term pregnancies: a study group with prenatally diagnosed late FGR, and a control group with normal fetal growth. Following delivery, cord blood samples from both groups will be analyzed for S100B protein concentrations, pH, base excess (BE), and lactate levels. Additionally, fetal blood flow parameters in the umbilical artery (UA), uterine arteries (UtA), ductus venosus (DV), and middle cerebral artery (MCA) will be monitored via ultrasound within 48 hours before delivery. This study aims to compare S100B protein concentrations in umbilical cord blood between the two groups and to assess correlations with fetal Doppler parameters, pH, BE, and lactate levels in cord blood gas analysis. Ultimately, we seek to determine the effectiveness of S100B protein concentration as a biomarker for diagnosing fetal CNS hypoxia- ischemia in FGR-affected children, compared to those with normal growth.",[212,213,30],"s100b","Hypoxia-Ischemia, Brain",[215,216,217,218,219],"S100B protein","fetal growth restriction (FGR)","newborn","central nervous system (CNS) damage","CNS hypoxia-ischemia (HI)","2025-03-24",{"date":222,"type":36},"2025-03-25",{"date":224,"type":36},"2024-06-18",{"date":226,"type":23},"2026-03-31",{"name":228,"class":43},"Institute of Mother and Child, Warsaw, Poland"]